2021
DOI: 10.1126/sciadv.abj0534
|View full text |Cite
|
Sign up to set email alerts
|

Iron oxide nanoparticles augment the intercellular mitochondrial transfer–mediated therapy

Abstract: The transfer of mitochondria between cells has recently been revealed as a spontaneous way to protect the injured cells. However, the utilization of this natural transfer process for disease treatment is so far limited by its unsatisfactory transfer efficiency and selectivity. Here, we demonstrate that iron oxide nanoparticles (IONPs) can augment the intercellular mitochondrial transfer from human mesenchymal stem cells (hMSCs) selectively to diseased cells, owing to the enhanced formation of connexin 43-conta… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
47
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 67 publications
(47 citation statements)
references
References 49 publications
0
47
0
Order By: Relevance
“…The content of ATP was measured with a commercial kit (BC0300, Solarbio Life Sciences, Beijing, China) following the instruction provided elsewhere (Huang et al ., 2021). The activity of ATPase was measured with a commercial kit (A016‐1‐1, Nanjing Jiancheng Bioengineering Institute, Nanjing, China) following the instruction provided elsewhere (Li et al ., 2017).…”
Section: Methodsmentioning
confidence: 99%
“…The content of ATP was measured with a commercial kit (BC0300, Solarbio Life Sciences, Beijing, China) following the instruction provided elsewhere (Huang et al ., 2021). The activity of ATPase was measured with a commercial kit (A016‐1‐1, Nanjing Jiancheng Bioengineering Institute, Nanjing, China) following the instruction provided elsewhere (Li et al ., 2017).…”
Section: Methodsmentioning
confidence: 99%
“…Ionized IONPs promote the formation of C×43-containing GJCs (C×43-GJCs), which selectively promote the transfer of hMSC mitochondria to damaged cells. In a mouse model of pulmonary fibrosis, IONP-engineered hMSCs promoted intercellular mitochondrial transfer and significantly alleviated fibrosis progression without any safety concerns [ 159 ].…”
Section: Strategies For Mitochondrial-transfer Optimizationmentioning
confidence: 99%
“…These properties make MSCs suitable for ARDS treatment [32]. MSCs have been used to treat lung injury in the preclinical settings [33][34][35][36][37]. Of the 42 registered clinical trials on ARDS treatment, seven have been completed, according to the US National Institutes of Health (https:// clini caltr ials.…”
Section: Msc-based Therapymentioning
confidence: 99%